Comparative effectiveness in urology: a state of the art review utilizing a systematic approach

Curr Opin Urol. 2017 Jul;27(4):380-394. doi: 10.1097/MOU.0000000000000405.

Abstract

Purpose of review: Comparative effectiveness research plays a vital role in healthcare delivery by guiding evidence-based practices. We performed a state-of-the-art review of comparative effectiveness research in the urology literature for 2016, utilizing a systematic approach. Seven high-impact papers are reviewed in detail.

Recent findings: Across the breadth of urology, there were several important studies in comparative effectiveness research, of which we will highlight two randomized controlled trials and five observational trials: radiotherapy, prostatectomy, and active monitoring have equivalent mortality outcomes in patients with localized prostate cancer; the ideal modality of patient education is yet to be determined, and written education has minimal effect on patient perception of prostate specific antigen screening; robotic prostatectomy is associated with higher perioperative complication rates on a population basis; racial disparities exist in incontinence rates after treatment for localized prostate cancer, but not in irritative, bowel, or sexual function; androgen deprivation therapy is associated with higher fracture, peripheral artery disease, and cardiac-related complications than bilateral orchiectomy; robotic and open cystectomy offer comparable cancer-specific mortality and perioperative outcomes; and bonuses for low-cost hospitals can inadvertently reward low-quality hospitals.

Summary: There have been major advancements in comparative effectiveness research in urology in 2016.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Comparative Effectiveness Research*
  • Humans
  • Male
  • Neoadjuvant Therapy
  • Observational Studies as Topic
  • Prostate-Specific Antigen / blood
  • Prostatectomy / adverse effects*
  • Prostatic Neoplasms / therapy*
  • Radiotherapy / adverse effects*
  • Randomized Controlled Trials as Topic
  • Urology* / trends

Substances

  • Prostate-Specific Antigen